Probity Advisors Inc. Has $1.21 Million Position in Pfizer Inc. $PFE

Probity Advisors Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 20.0% during the second quarter, Holdings Channel reports. The institutional investor owned 49,699 shares of the biopharmaceutical company’s stock after purchasing an additional 8,268 shares during the quarter. Probity Advisors Inc.’s holdings in Pfizer were worth $1,205,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Liberty One Investment Management LLC raised its position in Pfizer by 11.3% in the 2nd quarter. Liberty One Investment Management LLC now owns 1,225,408 shares of the biopharmaceutical company’s stock valued at $29,704,000 after buying an additional 123,945 shares during the last quarter. Privium Fund Management B.V. raised its position in Pfizer by 14.5% in the 2nd quarter. Privium Fund Management B.V. now owns 37,029 shares of the biopharmaceutical company’s stock valued at $927,000 after buying an additional 4,702 shares during the last quarter. Phoenix Financial Ltd. raised its position in Pfizer by 67.3% in the 2nd quarter. Phoenix Financial Ltd. now owns 76,603 shares of the biopharmaceutical company’s stock valued at $1,856,000 after buying an additional 30,805 shares during the last quarter. Berkeley Capital Partners LLC raised its position in Pfizer by 5.2% in the 2nd quarter. Berkeley Capital Partners LLC now owns 75,812 shares of the biopharmaceutical company’s stock valued at $1,838,000 after buying an additional 3,768 shares during the last quarter. Finally, Avidian Wealth Enterprises LLC raised its position in Pfizer by 9.4% in the 2nd quarter. Avidian Wealth Enterprises LLC now owns 19,945 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 1,712 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PFE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. UBS Group restated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America raised their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Morgan Stanley decreased their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Price Performance

Pfizer stock opened at $24.68 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.22. The stock has a market capitalization of $140.33 billion, a P/E ratio of 13.13, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The stock has a fifty day moving average of $24.89 and a 200-day moving average of $24.12.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the company posted $0.60 EPS. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.